Germany offers three layers of non-dilutive funding for MedTech startups: the federal EXIST programme for university spin-outs, BMBF research grants for applied health research, and state-level programmes run by each Bundesland. Each layer ties disbursement to milestones. And for MedTech those milestones map directly onto MDR regulatory progress.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • Germany has one of the deepest non-dilutive funding stacks in Europe for MedTech startups at the pre-seed and seed stage.
  • EXIST supports university-based founders through team grants and early company-formation funding.
  • BMBF funds applied health and biomedical research, often in consortia with universities and clinics.
  • Every Bundesland operates its own state-level funding programmes. Terms, sizes, and eligibility vary widely.
  • Regulatory milestones (classification, QMS build, first clinical data) are increasingly used as grant disbursement triggers.
  • Grant writing in Germany is a specific craft. Budget 6 to 12 weeks per serious application.

Why German non-dilutive funding matters

Germany has a large, decentralised, and historically generous public funding landscape for MedTech. The deep reason is that MedTech sits at the intersection of two German policy priorities: industrial competitiveness (the Mittelstand tradition of high-precision medical devices) and healthcare innovation (an ageing population and a public healthcare system under cost pressure). Both priorities survive changes in government, which means non-dilutive funding for MedTech is one of the more stable lines in the federal and state budgets.

For a founding team, this matters because German non-dilutive funding can cover the most expensive 18 to 24 months of a MedTech company's life. The period when you are building the QMS, running the first studies, drafting the technical documentation, and have zero revenue. Every euro of grant money is a euro you do not give up in equity. If you are a German or EU founder targeting the German market, ignoring this stack is an expensive mistake.

One caution before we dive in: the specific programme names, amounts, and eligibility rules change. Treat the structure below as reliable and the specific numbers as things to verify on the current programme pages before you apply.

The three layers of German funding

Layer 1. Federal programmes (EXIST and BMBF)

EXIST is the federal programme that supports university-based startup teams. The core building blocks most MedTech founders use are:

  • EXIST Business Start-up Grant (EXIST-Gründerstipendium). Personal stipends plus material and coaching budget for a small founding team working on a university-originated idea.
  • EXIST Research Transfer (EXIST-Forschungstransfer). Two-phase support for research-intensive spin-outs, intended to bridge the gap between research output and a fundable company.

EXIST is explicitly designed for teams still sitting inside a university. If you have already incorporated and left the university, you are usually too late for EXIST and need to look at other programmes.

BMBF (the Federal Ministry of Education and Research) funds applied health research through a rolling set of calls. For MedTech startups the relevant thread usually runs through health-research or medical-technology framework programmes. . BMBF calls are typically consortium-based: a startup partners with a university group and often a clinical site, and the consortium submits jointly. This is both an opportunity (shared costs, shared credibility, access to clinical partners) and a constraint (you cannot move at startup speed, and the grant timeline is measured in years, not months).

Layer 2. State-level programmes (Bundesländer)

Every German state runs its own innovation funding. The programmes to be aware of, by general category:

  • Bavaria operates early-stage innovation grants through state-level agencies, with a pronounced MedTech cluster around Munich, Erlangen, and Würzburg.
  • Baden-Württemberg supports innovation through state banks and economic development agencies, with strong MedTech activity around Tübingen and Stuttgart.
  • North Rhine-Westphalia runs state innovation grants, with MedTech clusters around Aachen and the Rhine-Ruhr corridor.
  • Berlin-Brandenburg offers state programmes aligned with the Berlin health cluster.
  • Saxony supports innovation through state economic agencies, particularly around Dresden and Leipzig.

Every other Bundesland has equivalent instruments. The golden rule: your state of incorporation usually determines which state programmes you can access. Incorporating in the wrong Bundesland can lock you out of a material amount of non-dilutive funding.

Layer 3. Federal and state loan and guarantee instruments

Beyond pure grants, Germany has a deep stack of subsidised loans and guarantee instruments through KfW and state development banks. These are not free money, but they can bridge gaps at rates that no private lender would offer. For MedTech founders with some revenue or signed commitments, these instruments belong in the financing mix alongside grants and equity.

What MDR-relevance means for your grant application

German grant programmes are not MDR programmes. But the people evaluating your application know that for a medical device, the path from research to market runs through MDR. A strong German MedTech grant application treats the regulatory path as a de-risking argument, not a disclaimer.

MDR Article 10 sets out the general obligations of manufacturers. MDR Annex VIII sets the classification rules. A grant application that shows the evaluator you understand your device class, have a credible QMS plan, and have mapped your milestones against regulatory work will score higher on feasibility than one that hand-waves the regulatory path. This is not because grant evaluators are regulatory experts. Many are not. It is because a founder who can explain the regulatory path credibly looks like a founder who will actually ship the device.

The concrete lever: tie your grant work packages to regulatory milestones. A work package called "complete design verification and risk management file per EN ISO 14971:2019+A11:2021" is specific, measurable, and obviously productive. A work package called "regulatory preparation" is vague and scores poorly.

A worked example: a EUR 1.4M stack for a university spin-out

A team of three researchers at a German technical university. Two engineers and a clinical collaborator. Were spinning out a Class IIa active diagnostic device. Over roughly 28 months they assembled the following non-dilutive stack (numbers rounded and illustrative, check current programme caps before planning yours):

  • EXIST Research Transfer Phase 1. Team stipends, materials, and coaching budget during the final university-based development phase.
  • State-level innovation grant from their Bundesland. Matched funding for prototype development and initial user studies.
  • BMBF consortium project. A three-year collaborative project with their former university group and a university hospital, covering clinical data generation that fed directly into the clinical evaluation.
  • KfW-backed working-capital line. Used selectively for cashflow bridging around milestone payments.

Three things made this stack work. First, they incorporated in a Bundesland that actively funded their category. Second, every application explicitly mapped work packages to MDR regulatory deliverables (classification rationale, QMS, risk management file, clinical evaluation plan). Third, they started writing the next application while the current one was being evaluated. The funding pipeline never went dry.

The Subtract to Ship playbook for German non-dilutive funding

Step 1. Map your regulatory milestones before you write the first grant. Know your device class under MDR Annex VIII. Know your conformity assessment route. Know the three or four major deliverables (QMS certification, technical documentation completion, clinical data milestones, Notified Body submission). These become the backbone of every grant work plan.

Step 2. Pick your incorporation Bundesland deliberately. If you have a choice, incorporate where the state-level programmes are strongest for your device category. This is a decision you make once and live with for years.

Step 3. If you are still at a university, apply for EXIST first. EXIST is the deepest and most founder-friendly layer, but the window closes once you incorporate and leave the university. Do not miss it.

Step 4. Build your BMBF consortium before the call opens. BMBF consortium calls are not open competitions you enter cold. They are relationships you build months in advance with a university group and a clinical partner. The consortium forms first; the grant follows.

Step 5. Budget 6 to 12 weeks per serious grant application. German grant writing is a specific craft. The forms are long. The evaluators read carefully. The difference between a funded and rejected application is often 30 pages of specific, well-structured work package descriptions.

Step 6. Tie work packages to regulatory deliverables. Every work package should produce a concrete output. "Risk management file per EN ISO 14971:2019+A11:2021" is a concrete output. "Explore regulatory options" is not.

Step 7. Keep a running pipeline. Apply for the next grant while the current one is being evaluated. The cash runway compounds only if the pipeline never empties.

Reality Check

  1. Do you know exactly which Bundesland's state programmes you are eligible for based on your incorporation?
  2. Have you checked whether you still qualify for EXIST, or have you already disqualified yourself by incorporating?
  3. Can you name a university group and a clinical partner who would join you in a BMBF consortium?
  4. Are your grant work packages tied to specific MDR regulatory deliverables with verifiable outputs?
  5. Do you have a written funding pipeline showing the next three applications and their submission dates?
  6. Have you budgeted the human time cost of grant writing (6 to 12 weeks per serious application)?
  7. Can you state your MDR device class and justify it in one paragraph to a non-regulatory grant evaluator?
  8. Have you verified the current programme names, amounts, and deadlines on the official programme pages. Not from an outdated blog post?

Frequently Asked Questions

Can I apply for EXIST if I have already left my university? Usually no. EXIST is designed for teams still operating from within a university setting. Once you have incorporated and left the academic environment, you normally need to look at state-level innovation programmes or federal research calls instead.

Do German grants count as dilutive or non-dilutive funding? Pure grants are non-dilutive. You do not give up equity. Some state instruments are structured as convertible loans or equity-linked grants, so read the terms carefully. KfW loans are debt, not equity.

Can a non-German EU founder access German state programmes? State programmes usually require the company to be incorporated and operating in that Bundesland. EU citizenship is typically not a barrier; German incorporation usually is a requirement.

How long does a BMBF consortium application take to evaluate? Typically several months from submission to decision, with an additional onboarding period before funds actually flow. Plan your runway accordingly. BMBF is strategic, not emergency, funding.

Should I hire a grant-writing consultant? For your first major federal or state application, many teams find it worth it. The specific format conventions and evaluator expectations are hard to learn from scratch. By your second or third application, you should be able to write in-house.

Can I combine EXIST with state-level funding? Often yes, but you must check the cumulation rules on each specific programme. EU state aid rules limit total public support to a given percentage of eligible costs, and double-funding the same work package from two sources is not allowed.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 10, Annex VIII.
  2. EN ISO 13485:2016+A11:2021. Medical devices. Quality management systems. Requirements for regulatory purposes.
  3. EN ISO 14971:2019+A11:2021. Medical devices. Application of risk management to medical devices.